Breaking Finance News

ValuEngine downgraded Egalet Corp (NASDAQ:EGLT) to Strong Sell in a report released today.

ValuEngine has downgraded Egalet Corp (NASDAQ:EGLT) to Strong Sell in a report released on 06/02/2017.

Previously on 5/12/2017, Gabelli released a statement for Egalet Corp (NASDAQ:EGLT) bumped up the target price from $0.00 to $9.50. At the time, this indicated a possible upside of 2.45%.

Having a price of $2.48, Egalet Corp (NASDAQ:EGLT) traded 0.95% higher on the day. With the last close up -50.20% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.03% over the same period. EGLT has recorded a 50-day average of $1.28 and a two hundred day average of $2.13. Trading volume was up over the average, with 780,177 shares of EGLT changing hands over the typical 455,720

Performance Chart

Egalet Corp (NASDAQ:EGLT)

With a total market value of $0, Egalet Corp has with a one year low of $0.97 and a one year high of $10.00 .

A total of 5 brokerages have issued a ratings update on Egalet Corp. 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 brokers rating the stock a hold, zero equity analysts rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $18.20.

General Company Details For Egalet Corp (NASDAQ:EGLT)

Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company's products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology. The Company's product SPRIX Nasal Spray, which contains ketorolac tromethamine is a non-steroidal anti-inflammatory drug (NSAID) indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level. The Company's product OXAYDO is an approved immediate-release (IR) oxycodone product formulated to deter abuse through snorting. The Company's product candidate, ARYMO ER is an abuse-deterrent (AD), extended-release (ER), oral morphine formulation. The Company's product candidate, Egalet-002, is an abuse-deterrent, extended-release, oral oxycodone formulation.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.